Latham & Watkins Advises IRRAS on Acquisition by ClearPoint Neuro

IRRAS Holdings Inc., a medical device company specializing in neurocritical care, has completed the sale of 100% of its shares to ClearPoint Neuro, Inc. (NASDAQ: CLPT), for a mix of cash and shares of ClearPoint common stock, plus additional earnout payments based on net sales after closing. The shares of ClearPoint delivered to the IRRAS stockholders may be sold pursuant to a registration statement that ClearPoint will file with the SEC after closing. This strategic transaction is expected to enable IRRAS to expand its market presence and enhance its commercial capabilities as part of the ClearPoint portfolio.

Latham & Watkins represents IRRAS with a corporate deal team led by New York partner Eli Curi and Los Angeles partner Brian Duff, with associate Drew O’Sullivan, and with assistance from Donara Aghajani. Advice was also provided on tax matters by Washington D.C. partner Andrea Ramezan-Jackson and on benefits matters by Silicon Valley partner James Robinson.